Compound Contains Two Or More C(=o)o Groups Patents (Class 514/547)
  • Patent number: 11339114
    Abstract: The present invention is directed to pharmaceutical compositions comprising compounds found in Harderian gland secretions, a method of treating dry eye in a human comprising ophthalmically administering an effective amount of a compound, e.g. a lipid compound, found in Harderian gland secretions, pharmaceutical compositions comprising said lipid compounds, as identified by characteristic chemical data and mass spectra of said lipid compounds, said lipid compound in essentially pure form, and an ophthalmic vehicle comprising a therapeutic agent and a compound present in the secretions of the Harderian gland, e.g. a lipid compound, found in the secretions of the Harderian gland, e.g. a rabbit Harderian gland.
    Type: Grant
    Filed: May 21, 2018
    Date of Patent: May 24, 2022
    Assignee: RestorTears, LLC
    Inventors: Daniel M. Albert, Arthur S. Polans
  • Patent number: 11332432
    Abstract: Compounds, compositions, and methods related to bioenergetic metabolism are provided. The compounds and com positions are suited to promote bioenergetic processes including cellular respiration and glycolytic flux and may be used to treat mitochondrial disorders, neurodegenerative diseases (such as Alzheimer's disease (AD), Parkinson's disease, and/or amyotrophic lateral sclerosis), multiple sclerosis, and/or epilepsy.
    Type: Grant
    Filed: September 30, 2019
    Date of Patent: May 17, 2022
    Assignee: University of Kansas
    Inventors: Russell Swerdlow, Laird Forrest, Jordan Hunt, Heather Wilkins, Eli Michaelis
  • Patent number: 11311750
    Abstract: The invention relates to a lubricating member for a razor cartridge comprising a metathesized unsaturated polyol ester for improved lubrication.
    Type: Grant
    Filed: June 26, 2017
    Date of Patent: April 26, 2022
    Assignee: The Gillette Company LLC
    Inventors: Luke Andrew Zannoni, Beth Ann Schubert, Rajan Keshav Panandiker, Joseph Jay Kemper, Robert John Strife, Safa Motlagh, Jeffrey John Scheibel, Alison Fiona Stephens, Philip Andrew Sawin
  • Patent number: 11285123
    Abstract: The present invention relates to compounds effective in treating hepatotoxicity and fatty liver diseases and uses thereof. The present compound is represented by Formula (II), which has the formula: R1—O—X—(CH2)m—X—O—R2, wherein: each X is —C(?O)—; R1 is a C1-C18 alkyl polyol: R2 is a saccharide group of formula (G)p; G is a monosaccharide residue, where (i) at least one of the —OH groups in (G)p is substituted by a halogen atom, and (ii) the saccharide group of formula (G)p is linked to —O— through a —CH2 group; p is 1 or 2; and m is 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10.
    Type: Grant
    Filed: September 17, 2019
    Date of Patent: March 29, 2022
    Assignee: SINEW PHARMA INC.
    Inventors: Oliver Yoa-Pu Hu, Tung-Yuan Shih, Cheng-Huei Hsiong, Hsin-Tien Ho
  • Patent number: 11281638
    Abstract: A system, method, and computer-readable medium for consolidating multiple databases into a single or a smaller number of databases is described. An improved structure of target database may be achieved by removing constraints used when creating legacy databases. According to some aspects, these and other benefits may be achieved by combining multiple source tables into a single target table with errors being identified and addressed during the creation of the instructions to generate the target table. In implementation, this may be effected by converting values from a source table and values from a target table into normalized versions of those values and then comparing the normalized values. A benefit includes verifying that the data from the source table is being properly reflected in the target table.
    Type: Grant
    Filed: April 22, 2020
    Date of Patent: March 22, 2022
    Assignee: Capital One Services, LLC
    Inventors: Dennis J. Mire, Kishore Doppalapudi
  • Patent number: 11273139
    Abstract: The present disclosure describes novel PKC-? activators chosen from halogenated esters of unsaturated fatty acids and derivatives thereof, including halogenated esters of both polyunsaturated and monounsaturated fatty acids and derivatives thereof. The disclosure further relates to compositions, kits, and methods for treatment using the halogenated esters.
    Type: Grant
    Filed: January 25, 2019
    Date of Patent: March 15, 2022
    Assignee: Synaptogenix, Inc.
    Inventors: Thomas J. Nelson, Daniel L. Alkon
  • Patent number: 11246850
    Abstract: Provided herein are methods of treating multiple sclerosis with a fumarate, wherein the fumarate is a dialkyl fumarate, a monoalkyl fumarate, a combination of a dialkyl fumarate and a monoalkyl fumarate, a prodrug of monoalkyl fumarate, a deuterated form of any of the foregoing, or a pharmaceutically acceptable salt, clathrate, solvate, tautomer, or stereoisomer of any of the foregoing, or a combination of any of the foregoing. The methods provided herein improve the safety of treatment by informing and monitoring patients undergoing treatment regarding progressive multifocal leukoencephalopathy, and/or by monitoring lymphocyte count.
    Type: Grant
    Filed: May 17, 2021
    Date of Patent: February 15, 2022
    Assignee: Biogen MA Inc.
    Inventors: Mark Novas, Rui (Ray) Zhang
  • Patent number: 11229621
    Abstract: Pharmaceutical compositions and dosage forms of dimethyl fumarate containing low levels of certain impurities are disclosed.
    Type: Grant
    Filed: January 22, 2020
    Date of Patent: January 25, 2022
    Assignee: Arbor Pharmaceuticals, LLC
    Inventors: Sami Karaborni, Wei Chen, Suresh Kumar Manthati
  • Patent number: 11135156
    Abstract: A pharmaceutical tablet for use in administering one or more pharmaceutically active ingredients, comprising a polymer system, the one or more pharmaceutically active ingredients, a flavor, and a sweetener, wherein at least 20% by weight of the pharmaceutical tablet comprises substantially non-elastomeric polymer and less than 5% by weight of the pharmaceutical tablet comprises one or a combination of elastomeric polymers, and wherein the pharmaceutical tablet comprises at least 70% by weight of said polymer system comprising polyvinyl acetate (PVA) and less than 10% by weight of said polymer system comprising polymer having a molecular weight (Mw) greater than 50,000 g/mol.
    Type: Grant
    Filed: May 23, 2017
    Date of Patent: October 5, 2021
    Assignee: FERTIN PHARMA A/S
    Inventors: Martin Topsoe, Kirsten Lund
  • Patent number: 11129806
    Abstract: Provided herein are methods of treating multiple sclerosis with a fumarate, wherein the fumarate is a dialkyl fumarate, a monoalkyl fumarate, a combination of a dialkyl fumarate and a monoalkyl fumarate, a prodrug of monoalkyl fumarate, a deuterated form of any of the foregoing, or a pharmaceutically acceptable salt, clathrate, solvate, tautomer, or stereoisomer of any of the foregoing, or a combination of any of the foregoing. The methods provided herein improve the safety of treatment by informing and monitoring patients undergoing treatment regarding progressive multifocal leukoencephalopathy, and/or by monitoring lymphocyte count.
    Type: Grant
    Filed: July 11, 2017
    Date of Patent: September 28, 2021
    Assignee: Biogen MA Inc.
    Inventors: Mark Novas, Rui (Ray) Zhang
  • Patent number: 11123276
    Abstract: The present disclosure relates to compositions and methods for treating and/or cleansing keratinous materials. The compositions comprise at least one carboxylate anionic surfactant, at least one secondary surfactant other than the at least one carboxylate anionic surfactant, at least one glyceryl ester, and a cosmetically acceptable solvent, wherein the at least one carboxylate anionic surfactant and the at least one glyceryl ester are present in a weight ratio ranging from about 0.50 to about 1.00.
    Type: Grant
    Filed: February 28, 2018
    Date of Patent: September 21, 2021
    Assignee: L'OREAL
    Inventors: Jun Liang, Heather Lee, Angela Park
  • Patent number: 11052062
    Abstract: The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of e.g. psoriasis or other hyperproliferative, inflammatory or autoimmune disorders and are designated to release the fumaric acid ester in a controlled manner so that local high concentrations of the active substance within the gastrointestinal tract upon oral administration can be avoided and, thereby, enabling a reduction in gastro-intestinal related side-effects.
    Type: Grant
    Filed: July 29, 2019
    Date of Patent: July 6, 2021
    Assignee: Biogen Swiss Manufacturing GmbH
    Inventors: Henrik Nilsson, Bernd W. Mueller
  • Patent number: 11020403
    Abstract: Embodiments of the invention are directed to formulations that provide a solution to the problem of small molecule (e.g., diazepam) precipitation at the injection site when administered as a highly-concentrated formulation. In certain aspects the formulations include at least one surfactant in a non-aqueous formulation, which prevents small molecule precipitation and improves the bioavailability of the drug by enhancing absorption into the systemic circulation.
    Type: Grant
    Filed: May 31, 2018
    Date of Patent: June 1, 2021
    Assignee: Xeris Pharmaceuticals, Inc.
    Inventors: Steven J. Prestrelski, Michael A. Sandoval, Brian R. Sloat
  • Patent number: 11007167
    Abstract: Provided herein are methods of treating multiple sclerosis with a fumarate, wherein the fumarate is a dialkyl fumarate, a monoalkyl fumarate, a combination of a dialkyl fumarate and a monoalkyl fumarate, a prodrug of monoalkyl fumarate, a deuterated form of any of the foregoing, or a pharmaceutically acceptable salt, clathrate, solvate, tautomer, or stereoisomer of any of the foregoing, or a combination of any of the foregoing. The methods provided herein improve the safety of treatment by informing and monitoring patients undergoing treatment regarding progressive multifocal leukoencephalopathy, and/or by monitoring lymphocyte count.
    Type: Grant
    Filed: October 15, 2020
    Date of Patent: May 18, 2021
    Assignee: Biogen MA Inc.
    Inventors: Mark Novas, Rui (Ray) Zhang
  • Patent number: 11000541
    Abstract: Disclosed herein is a medicine composition for facilitating treating organs of a mammal, in accordance with some embodiments. Accordingly, the medicine composition may include carbanions and a diluting agent. Further, a carbanion of the carbanions may include a carbon atom. Further, the carbon atom may include a formal charge of ?1. Further, the diluting agent may be capable of combining with the carbanions for forming at least one appliable form of the medicine composition. Further, a ratio of the diluting agent to the carbanions by volume ranges from 512:1 to 32:1. Further, the combining facilitates applying of the at least one appliable form of the medicine composition to at least one organ of the mammal.
    Type: Grant
    Filed: February 11, 2021
    Date of Patent: May 11, 2021
    Inventor: Donald Richard Wilshe
  • Patent number: 10959972
    Abstract: Provided herein are methods of treating multiple sclerosis with a fumarate, wherein the fumarate is a dialkyl fumarate, a monoalkyl fumarate, a combination of a dialkyl fumarate and a monoalkyl fumarate, a prodrug of monoalkyl fumarate, a deuterated form of any of the foregoing, or a pharmaceutically acceptable salt, clathrate, solvate, tautomer, or stereoisomer of any of the foregoing, or a combination of any of the foregoing. The methods provided herein improve the safety of treatment by informing and monitoring patients undergoing treatment regarding progressive multifocal leukoencephalopathy, and/or by monitoring lymphocyte count.
    Type: Grant
    Filed: October 29, 2018
    Date of Patent: March 30, 2021
    Assignee: BIOGEN MA INC.
    Inventors: Mark Novas, Rui (Ray) Zhang
  • Patent number: 10960044
    Abstract: The present disclosure relates to the field of health care products, disclosing a powder made from inulin, FOLIUM CYCLOCARYA PALIURUS, RHIZOMA DIOSCOREA OPPOSITE, RADIX ASTRAGALUS MEMBRANACEUS, CAULIS DENDROBIUM and RADIX ET RHIZOMA SALVIA MILTIORRHIZA. The raw materials of the powder are all from natural Chinese herbal medicine without addition of excipient. In addition, dosage required for the powder is small; it can be directly dissolved in water for taking; it is soluble in cold water and can be absorbed quickly. The method for preparing the powder in the present disclosure is simple and suitable for large-scale production. Also, it is easy to be carried. The powder obtained has a good stability and long storage time. Experiments show that the powder of the present disclosure has greatly hypoglycemic and hypolipidemic effects, therefore can be used to prepare the health care foods having hypoglycemic and hypolipidemic effect.
    Type: Grant
    Filed: July 9, 2018
    Date of Patent: March 30, 2021
    Assignee: INFINITUS (CHINA) COMPANY LTD.
    Inventors: Fang Lv, Hongwei Zhao, Qingtao Tang
  • Patent number: 10918614
    Abstract: The present invention provides a compound which is a polyunsaturated fatty acid (PUFA) derivative of formula (I), or a pharmaceutically acceptable salt, or solvate thereof, for use in treating various skin disorders.
    Type: Grant
    Filed: June 24, 2019
    Date of Patent: February 16, 2021
    Inventors: Adam Kelliher, Angus Morrison, Phil Knowles
  • Patent number: 10857119
    Abstract: The present invention relates to a composition containing a monoacetyldiglyceride compound as an active ingredient, for inhibiting blood cancer or metastasis, and a use thereof. The monoacetyldiglyceride compound according to the present invention has excellent effects of inhibiting the expression of IL-4 and inhibiting the activity of STAT-6, and thereby is capable of overcoming side effects of currently used blood cancer or metastasis inhibiting agents. Also, the monoacetyldiglyceride compound is a non-toxic compound having superior therapeutic effects and thus can be useful as a composition for preventing, treating, or improving blood cancer and metastasis.
    Type: Grant
    Filed: July 25, 2018
    Date of Patent: December 8, 2020
    Assignees: Enzychem Lifesciences Corporation, Korea Research Institute of Bio Science and Biotechnology
    Inventors: Jae Wha Kim, Sei-Ryang Oh, Kyung Seop Ahn, Ho Bum Kang, Jae Min Shin, Young Eun Ko, Tae Suk Lee, Myung Hwan Kim, Jong Koo Kang, Yong-Hae Han, Ki-Young Sohn
  • Patent number: 10835508
    Abstract: One embodiment described herein is related to methods and compositions, such as nutraceutical formulations and dietary supplements, comprising C16:1n7-palmitoleate or derivatives thereof. The methods and compositions comprising C16:1n7-palmitoleate, or derivatives thereof, safely and effectively prevent or mitigate manifestations of cardiovascular disease, including coronary artery disease and the accumulation of cholesterol or lipid deposits in the blood vessels of a subject.
    Type: Grant
    Filed: May 8, 2019
    Date of Patent: November 17, 2020
    Assignee: TERSUS LIFE SCIENCES, LLC
    Inventor: Jeffrey Green
  • Patent number: 10813905
    Abstract: Methods of using one or more fumaric acid esters or pharmacologically active salts, derivatives, analogues, or prodrugs thereof to increase expression of fetal hemoglobin (HbF) are disclosed. The methods typically include administering to a subject an effective amount of one or more fumaric acid esters optionally in combination or alternation with hydroxyurea to induce HbF expression in the subject in an effective amount to reduce one or more symptoms of a sickle cell disorder, a hemoglobinopathy, or a beta-thalassemia, or to compensate for a genetic mutation is the human beta-globin gene (HBB) or an expression control sequence thereof. Pharmaceutical dosage units and dosage regimes for use in the disclosed methods are also provided.
    Type: Grant
    Filed: August 1, 2017
    Date of Patent: October 27, 2020
    Assignee: Augusta University Research Institute, Inc.
    Inventors: Vadivel Ganapathy, Pamela M. Martin
  • Patent number: 10774031
    Abstract: The present disclosure discloses prodrugs of gamma-hydroxybutyric acid as well as compositions and uses thereof.
    Type: Grant
    Filed: March 26, 2020
    Date of Patent: September 15, 2020
    Assignee: XW LABORATORIES INC.
    Inventors: Jia-Ning Xiang, Xuesong Xu, Xuan Zhang
  • Patent number: 10668013
    Abstract: An oral pharmaceutical composition in unit dose form, each unit dose comprising a lipophilic drug substance within a unitary carrier body, said body comprising a soft, chewable, gelled oil-in-water emulsion.
    Type: Grant
    Filed: June 30, 2017
    Date of Patent: June 2, 2020
    Assignee: VITUX GROUP AS
    Inventors: Tore Seternes, Kurt Ingar Draget, Ingvild Johanne Haug
  • Patent number: 10660958
    Abstract: An organoleptically acceptable composition containing a ketone body or a ketone body precursor including a hydroxybutyrate ester and a flavouring is provided and gives improved palatability and user adherence to the intended dose regime. The flavouring may be a bitter flavouring and the composition may further contain an adsorbent for the ketone such that on ingestion, the bitterness of the composition may be masked. The composition may be in the form of a solid, gel or liquid and provides increased blood ketone levels and may be used in therapy or in treating muscle impairment or fatigue.
    Type: Grant
    Filed: February 22, 2011
    Date of Patent: May 26, 2020
    Assignee: TDELTAS LIMITED
    Inventor: Kieran Clarke
  • Patent number: 10646462
    Abstract: Beta-hydroxybutyrate mineral salts in combination with medium chain fatty acids or an ester thereof such as medium chain triglycerides were used to induce ketosis, achieving blood ketone levels of (2-7 mmol/L), with or without dietary restriction. The combination results in substantial improvements in metabolic biomarkers related to insulin resistance, diabetes, weight loss, and physical performance in a short period of time. Further, use of these supplements to achieve ketosis yields a significant elevation of blood ketones and reduction of blood glucose levels. Use of these substances does not adversely affect lipid profiles. By initiating rapid ketosis and accelerating the rate of ketoadaptation, this invention is useful for the avoidance of glucose withdrawal symptoms commonly experienced by individuals initiating a ketogenic diet, and minimizes the loss of lean body mass during dietary restriction.
    Type: Grant
    Filed: June 1, 2017
    Date of Patent: May 12, 2020
    Assignee: University of South Florida
    Inventors: Dominic Paul D'Agostino, Patrick Arnold, Shannon Kesl
  • Patent number: 10640451
    Abstract: The present disclosure discloses prodrugs of gamma-hydroxybutyric acid as well as compositions and uses thereof.
    Type: Grant
    Filed: October 15, 2019
    Date of Patent: May 5, 2020
    Assignee: XW LABORATORIES INC.
    Inventors: Jia-Ning Xiang, Xuesong Xu, Xuan Zhang
  • Patent number: 10596141
    Abstract: The disclosure provides methods for treating, controlling or mitigating leukopenia (e.g. neutropenia) and/or thrombocytopenia, for example in the context of cancer chemotherapy, comprising administration of a monoacetyl-diacyl-glycerol compound, as well as compositions useful therefor.
    Type: Grant
    Filed: November 24, 2015
    Date of Patent: March 24, 2020
    Assignee: Enzychem Lifesciences Corporation
    Inventors: Ki-Young Sohn, Jae Wha Kim
  • Patent number: 10588886
    Abstract: The disclosure provides methods for treating, controlling or mitigating leukopenia (e.g. neutropenia) and/or thrombocytopenia, for example in the context of cancer chemotherapy, comprising administration of a monoacetyl-diacyl-glycerol compound, as well as compositions useful therefor.
    Type: Grant
    Filed: November 9, 2015
    Date of Patent: March 17, 2020
    Assignee: Enzychem Lifesciences Corporation
    Inventors: Ki-Young Sohn, Jae Wha Kim
  • Patent number: 10525028
    Abstract: [Problem] To provide a composition for external skin use that has anti-inflammatory and antiallergic activity, and is very safe. [Solution] A composition for external skin use for inflammatory diseases contains dihomo-gamma-linolenic acid (DGLA) as the active ingredient thereof. It is preferable for the DGLA to be present as a glyceride, a phospholipid, or an alkyl ester. The amount of DGLA contained in the composition for external use is 0.1-50 wt %.
    Type: Grant
    Filed: October 30, 2015
    Date of Patent: January 7, 2020
    Assignee: NIPPON SUISAN KAISHA, LTD.
    Inventors: Jiro Takeo, Hiroyuki Kawahara
  • Patent number: 10501401
    Abstract: The present disclosure discloses prodrugs of gamma-hydroxybutyric acid as well as compositions and uses thereof.
    Type: Grant
    Filed: February 13, 2019
    Date of Patent: December 10, 2019
    Assignee: XW LABORATORIES INC.
    Inventors: Jia-Ning Xiang, Xuesong Xu, Xuan Zhang
  • Patent number: 10434148
    Abstract: The present invention discloses a preparation method of an albumin peptide combination and the action of inhibiting the proliferation of cancer cells thereof, the preparation steps comprise: mixing albumin and water in proportion, heating, adjusting pH, adding alkaline protease to perform enzymatic hydrolysis, deactivating, filtrating; mixing Coix seed and water in proportion, decocting to extract, filtrating, adding certain proportional of water to filter residue, continue decocting to extract, collecting filtrates, determining solid matter content respectively, mixing two solutions, concentrating, spray drying, and obtaining an albumin peptide combination having the action of inhibiting the proliferation of cancer cells. The present invention found that, as compared with using Coix seed individually, the effect of inhibiting the proliferation of cancer cells of albumin peptide combination is stronger, and process is simpler.
    Type: Grant
    Filed: July 5, 2017
    Date of Patent: October 8, 2019
    Assignees: Nascent Peptide Biotechnology Limited
    Inventors: Dongliang Chen, Yang Zhang, Cong Zhou
  • Patent number: 10434340
    Abstract: A method of treating skin is disclosed. The method can include topically applying to skin in need thereof, an emulsion comprising palmitoyl tetrapeptide 7, water, glycerin, cetyl alcohol, denatured alcohol, stearic acid, dimethicone, squalane, mineral oil, and beeswax.
    Type: Grant
    Filed: October 31, 2017
    Date of Patent: October 8, 2019
    Assignee: Mary Kay Inc.
    Inventors: Dawn Burke-Colvin, Michelle Hines, David Gan
  • Patent number: 10414713
    Abstract: The present invention relates to a class of fatty acid compounds, a preparation method thereof and use thereof. The fatty acid compounds have the structure of the formula I, which has the ability to activate APMK and inhibit the glucose output in mouse primary hepatocytes. The fatty acid compounds can be used in preparing a medicament for the treatment of obesity or diabetes.
    Type: Grant
    Filed: February 20, 2017
    Date of Patent: September 17, 2019
    Assignee: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES
    Inventors: Fajun Nan, Jia Li, Jingya Li, Mei Zhang, Zhifu Xie, Jingtao Wang, Dongdong Guo
  • Patent number: 10383894
    Abstract: A medicinal drug is administered to a person for treating allergic rhinitis, hemorrhoids, toothache, bromhidrosis, or urticaria. The medicinal drug is formed at least partially with salt of peroxymonosulfuric acid, preferably potassium hydrogen peroxymonosulfate.
    Type: Grant
    Filed: March 17, 2010
    Date of Patent: August 20, 2019
    Assignee: LuTran Industries, Inc.
    Inventors: David Van Tran, David Nguyen Tran
  • Patent number: 10329579
    Abstract: The present invention pertains to methods, means and uses of nucleic acids and polypeptides for conferring, modifying or improving plant resistance against fungal infections. Particularly, the invention provides nucleic acids and polypeptides for conferring, modifying or improving plant resistance against fungal infections. The invention also provides vectors, cells and plants. Also, the invention provides methods for creating corresponding plant cells and plants, and for identification of agents for conferring, modifying or improving plant resistance against fungal infections.
    Type: Grant
    Filed: December 14, 2012
    Date of Patent: June 25, 2019
    Assignee: BASF PLANT SCIENCE COMPANY GMBH
    Inventors: Holger Schultheiss, Nadine Tresch, Uwe Conrath, Katharina Goellner, Caspar Langenbach
  • Patent number: 10328046
    Abstract: The present invention provides a compound which is a polyunsaturated fatty acid (PUFA) derivative of formula (I), or a pharmaceutically acceptable salt, or solvate thereof, for use in treating various skin disorders.
    Type: Grant
    Filed: December 28, 2017
    Date of Patent: June 25, 2019
    Assignee: DS Biopharma Limited
    Inventors: Adam Kelliher, Angus Morrison, Phil Knowles
  • Patent number: 10272056
    Abstract: The present application relates to methods of treating a subject with a disease or disorder associated with a mitochondrial deficit, comprising: determining at least one of a type or degree of the mitochondrial deficit in the subject; and administering an amount of a butyrate compound to the subject based at least partially on the determining step so as to promote Adenosine triphosphate (ATP) production in the subject as well as to methods of screening for compounds that restore cellular mitochondrial activity.
    Type: Grant
    Filed: April 1, 2016
    Date of Patent: April 30, 2019
    Assignee: The George Washington University, A Congressionally Chartered Not-for-Profit Corporation
    Inventors: Anne Chiaramello, Martine Uittenbogaard
  • Patent number: 10258593
    Abstract: A semiochemical composition including methyl laurate, methyl myristate, methyl palmitate, methyl linoleate, methyl oleate, methyl stearate, dimethyl pimelate, dimethyl azelate, salts thereof, derivatives thereof, isomers thereof and/or structural analogs thereof that maintain their semiochemical capabilities is described. Methods to reduce social conflicts in multi-cat households or in catteries or kennels boarding cats are also disclosed, as well as methods for inducing social facilitation in cats.
    Type: Grant
    Filed: March 17, 2015
    Date of Patent: April 16, 2019
    Assignee: INSTITUT DE RECHERCHE EN SEMIOCHIMIE ET ETHOLOGIE APPLIQUEE
    Inventor: Patrick Pageat
  • Patent number: 10259772
    Abstract: An object of the present invention is to find a novel substance that is capable of efficiently promoting the proliferation of stem cells while maintaining the undifferentiated state thereof and to provide the substance as an agent for maintaining the undifferentiated state of stem cells or an agent for promoting the proliferation of stem cells. Another object of the present invention is to provide an agent for treating a wound that has a wound healing effect on the skin and is readily available in the field of skin regenerative medicine or cosmetic treatment, and safe and inexpensive.
    Type: Grant
    Filed: November 5, 2015
    Date of Patent: April 16, 2019
    Assignee: Nippon Menard Cosmetic Co., Ltd.
    Inventors: Seiji Hasegawa, Yu Inoue, Yuichi Hasebe, Tsutomu Sakaida
  • Patent number: 10227434
    Abstract: The invention relates to a composition for use in a Monosil process for the crosslinking of thermoplastic polyolefins which comprises (i) from 5 to 60% by weight content of caprylic acid (H3C(CH2)6COOH), (ii) content of at least one monounsaturated organofunctional alkoxysilane of the general formula I A-SiR2x(OR1)3-x??(I), where R1 is mutually independently a linear or branched hydrocarbon moiety having from 1 to 4 C atoms, R2 is methyl and x is 0 or 1 and A is a monovalent olefin group of the formula (R3)2C?C(R3)-Mk-, where k is 0 or 1, in which groups R3 are identical or different and R3 is a hydrogen atom or a methyl group and the group M is a group from this list: —CH2—, —(CH2)2—, —(CH2)3— and C(O)O—(CH2)3—, (iii) content of at least one free-radical generator and (iv) optionally content of at least one other component, where the entirety of all components (i) to (iv) gives 100% by weight.
    Type: Grant
    Filed: July 29, 2014
    Date of Patent: March 12, 2019
    Assignee: Evonik Degussa GmbH
    Inventors: Aristidis Ioannidis, Ioana-Elena Mihailescu, Bastian Bielawski, Kerstin Weissenbach
  • Patent number: 10166209
    Abstract: In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.
    Type: Grant
    Filed: December 23, 2015
    Date of Patent: January 1, 2019
    Assignee: Amarin Pharmaceuticals Ireland Limited
    Inventors: Mehar Manku, Ian Osterloh, Pierre Wicker, Rene Braeckman, Paresh Soni, Joseph S. Zakrzewski
  • Patent number: 10130672
    Abstract: The present invention relates to a composition of phenolic antioxidants obtained from oil palm, and more particularly this invention relates to a composition for promoting immunity in general and most essentially against Human Immunodeficiency Virus (HIV) related infections. Accordingly, the composition having the said oil palm compounds can effectively inhibit various viruses, further supporting oil palm compounds as one of the broad spectrum antiviral drugs.
    Type: Grant
    Filed: October 1, 2012
    Date of Patent: November 20, 2018
    Assignee: Malaysian Palm Oil Board
    Inventors: Ravigadevi Sambanthamurthi, Kalyana Sundram P. Manickam, Yew Ai Tan, Mohd Basri bin Wahid
  • Patent number: 10123960
    Abstract: A double conjugate molecule made of a retinoid, an organic acid, particularly an a-hydroxy acid, and an alcohol or acyl group, is provided which is useful in treating skin conditions, particularly aging. The retinoid, organic acid, and alcohol/acyl group are preferably linked via ester bonds.
    Type: Grant
    Filed: November 14, 2014
    Date of Patent: November 13, 2018
    Assignee: PCR TECHNOLOGY HOLDINGS, LC
    Inventor: Joseph A. Lewis, II
  • Patent number: 10123554
    Abstract: The present invention pertains to a method for manufacturing a feed product comprising the steps of: providing a lactylate product, wherein the lactylate product comprises at least 30 wt, % of C10-C16-fatty acid lactylates, in liquid form at a first location; transferring lactylate product in the liquid form to a transport unit; transporting the lactylate product in the transport unit to a second location, with the lactylate product being in solid form, in liquid form, or in an intermediate state during transport; if the lactylate product is solidified or partly solidified, converting the lactylate product to the liquid form in the transport unit; removing the lactylate product from the transport unit in liquid form at the second location; and, contacting the lactylate product in liquid form with a feed product.
    Type: Grant
    Filed: October 27, 2014
    Date of Patent: November 13, 2018
    Assignee: PURAC BIOCHEM B.V.
    Inventors: Nikolaos Vogiatzis, Symone Kok, Barbara Lara Veldhuis-Stribos
  • Patent number: 10111848
    Abstract: Provided are methods for treating GLUT1 and related brain energy deficiencies comprising administering odd-carbon fatty acid sources, e.g., C5 or C7 fatty acid sources, and related compositions.
    Type: Grant
    Filed: September 6, 2016
    Date of Patent: October 30, 2018
    Assignees: National Institute of Health and Medical Research, Baylor Research Institute
    Inventors: Fanny Mochel, Raphael Schiffmann
  • Patent number: 10098964
    Abstract: The invention provides novel formulations comprising a stable inclusion complex of tributyrin and a cyclodextrin. In one particular embodiment, the formulation comprises an oven dried inclusion complex of tributyrin and ?-cyclodextrin that is effective in minimizing or preventing the unpleasant taste and odor of tributyrin, thus making it suitable for oral administration and delivery to the digestive tract and intestines. The invention provides compositions of these inclusion complexes and methods of using them that are advantageous as food, medicinal and other products, where the negative sensory properties of tributyrin can be a liability.
    Type: Grant
    Filed: March 14, 2016
    Date of Patent: October 16, 2018
    Assignee: The Board of Trustees of the University of Illinois
    Inventors: Joseph D. Donovan, Soo-Yeun Lee, Youngsoo Lee
  • Patent number: 10058527
    Abstract: The present invention relates to a composition containing a monoacetyldiglyceride compound as an active ingredient, for inhibiting blood cancer or metastasis, and a use thereof. The monoacetyldiglyceride compound according to the present invention has excellent effects of inhibiting the expression of IL-4 and inhibiting the activity of STAT-6, and thereby is capable of overcoming side effects of currently used blood cancer or metastasis inhibiting agents. Also, the monoacetyldiglyceride compound is a non-toxic compound having superior therapeutic effects and thus can be useful as a composition for preventing, treating, or improving blood cancer and metastasis.
    Type: Grant
    Filed: August 18, 2014
    Date of Patent: August 28, 2018
    Assignees: ENZYCHEM LIFESCIENCES CORPORATION, KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY
    Inventors: Jae Wha Kim, Sei Ryang Oh, Kyung Seop Ahn, Ho Bum Kang, Jae Min Shin, Young Eun Ko, Tae Suk Lee, Myung Hwan Kim, Jong Koo Kang, Yong-Hae Han, Ki-Young Sohn
  • Patent number: 10028928
    Abstract: Compositions comprising a fatty acid oil mixture and at least one free fatty acid, and uses thereof are disclosed. Further disclosed are preconcentrates capable of forming a self-nanoemulsifying drug delivery system (SNEDDS), a self-microemulsifying drug delivery system (SMEDDS) or self-emulsifying drug delivery systems (SEDDS) in an aqueous solution. Preferred fatty acids are eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in a form chosen from ethyl ester and triglyceride.
    Type: Grant
    Filed: November 14, 2016
    Date of Patent: July 24, 2018
    Assignee: Pronova Biopharma Norge AS
    Inventors: Svein Olaf Hustvedt, Preben Houlberg Olesen, Gunnar Berge, Anette Mullertz
  • Patent number: 10022346
    Abstract: The treatment options for treating blast-induced and noise-induced traumatic brain injury and tinnitus are limited. Thus, the current invention provides methods for treating traumatic brain injury and tinnitus. The methods involve administering a pharmaceutically effective amount of a composition comprising 2,4-disulfonyl ?-phenyl tertiary butyl nitrone and N-acetylcysteine (NAC).
    Type: Grant
    Filed: January 27, 2017
    Date of Patent: July 17, 2018
    Assignees: Hough Ear Institute, Oklahoma Medical Research Foundation
    Inventors: Richard D. Kopke, Robert A. Floyd, Rheal Towner
  • Patent number: 9969681
    Abstract: The present invention relates to trisodium diethylenetriamine pentaacetic acid (DTPA) prodrugs, such as, for example, DTPA di-ethyl esters. The invention further relates to compositions comprising DTPA prodrugs and methods of using the same.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: May 15, 2018
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: Michael Jay, Russell Mumper, James Huckle, Matthew Sadgrove